Stagezero Life Sciences (TSE:SZLS) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
StageZero Life Sciences has reported a decline in its Q1 2024 revenue to $0.523 million from the previous year’s $0.778 million, but also noted a significant reduction in net loss to $0.386 million from $1.812 million. The company highlighted advancements in partnerships and business development in North America and Europe, with a strategic focus on its proprietary Aristotle multi-cancer screening test and the upcoming launch of the COC Protocol 2.0.
For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.
